Glycogen synthase kinase-3: A potential preventive target for prostate cancer management

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 11, 2015, Pages 456-463

  Li, Benyi ^a   Thrasher, James Brantley ^a   Terranova, Paul ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cancer prevention and treatment; GSK 3; Lithium chloride; Prostate cancer; Small chemicals

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; WNT PROTEIN; ANTINEOPLASTIC AGENT; GSK3B PROTEIN, HUMAN;

CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; GENE EXPRESSION; GENE MUTATION; HUMAN; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; DRUG EFFECTS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84945436939     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.006     Document Type: Review

References (117)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2014. Ann Oncol 2014, 25:1650-1656.
3. Fraser M., Berlin A., Bristow R.G., van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol 2015, 33:85-94.
4. Barbieri C.E., Tomlins S.A. The prostate cancer genome: perspectives and potential. Urol Oncol 2014, 32:e15-e22.
5. Demichelis F., Stanford J.L. Genetic predisposition to prostate cancer: update and future perspectives. Urol Oncol 2015, 33:75-84.
6. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942, 115:1192-1200.
7. Quinn D.I., Vaishampayan U., Higano C.S., Lin D.W., Shore N.D., Beer T.M. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther 2014, 14:51-61.
8. Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014, 6:238ra70.
9. Gomez L., Kovac J.R., Lamb D.J. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015, 95C:80-87.
10. Carter H.B. Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis. Eur urol 2014, 66:973-974.
11. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
12. Jahn J.L., Giovannucci E.L., Stampfer M.J. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer 2014, http://dx.doi.org/10.1002/ijc.29408 [Epub ahead of print].
13. Hayes J.H., Barry M.J. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. J Am Med Assoc 2014, 311:1143-1149.
14. Overholser S., Nielsen M., Torkko K., Cwilka D., Weaver B., Shi X., et al. Active surveillance is an appropriate management strategy for a proportion of men diagnosed with prostate cancer by PSA testing. J Urol 2015, http://dx.doi.org/10.1016/j.juro.2015.01.089 [Epub ahead of print].
15. Mohammed A.A. Biomarkers in prostate cancer: new era and prospective. Med Oncol 2014, 31:140.
16. Helfand B.T., Catalona W.J., Xu J. A genetic-based approach to personalized prostate cancer screening and treatment. Curr Opin Urol 2015, 25:53-58.
17. Loeb S., Bruinsma S.M., Nicholson J., Briganti A., Pickles T., Kakehi Y., et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 2015, 67:619-626.
18. Simpkin A.J., Tilling K., Martin R.M., Lane J.A., Hamdy F.C., Holmberg L., et al. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol 2015, 67:993-1005.
19. Carter G., Clover K., Britton B., Mitchell A.J., White M., McLeod N., et al. Wellbeing during active surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev 2015, 41:46-60.
20. Richard P.O., Finelli A. 5-Alpha reductase inhibitors in active surveillance. Curr Opin Urol 2014, 24:324-328.
21. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
22. Cuzick J., Thorat M.A., Andriole G., Brawley O.W., Brown P.H., Culig Z., et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014, 15:e484-e492.
23. Thompson I.M., Cabang A.B., Wargovich M.J. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 2014, 11:49-60.
24. Barton M.K. Daily aspirin may reduce mortality from prostate cancer with risk of high recurrence. CA Cancer J Clin 2015, 65:83-84.
25. Debes J.D., Roberts R.O., Jacobson D.J., Girman C.J., Lieber M.M., Tindall D.J., et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 2004, 13:255-259.
26. Chen R., Zeng X., Zhang R., Huang J., Kuang X., Yang J., et al. Cav1.3 channel alpha1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol 2014, 32:524-536.
27. Grytli H.H., Fagerland M.W., Fossa S.D., Tasken K.A. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014, 65:635-641.
28. Cohen Y., Chetrit A., Cohen Y., Sirota P., Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 1998, 15:32-36.
29. Beurel E., Grieco S.F., Jope R.S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015, 148:114-131.
30. Lal H., Ahmad F., Woodgett J., Force T. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 2015, 116:138-149.
31. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Sokolosky M., Abrams S.L., et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014, 5:2881-2911.
32. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. FEBS J 1980, 107:519-527.
33. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990, 9:2431-2438.
34. Mukai F., Ishiguro K., Sano Y., Fujita S.C. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 2002, 81:1073-1083.
35. Li M., Wang X., Meintzer M.K., Laessig T., Birnbaum M.J., Heidenreich K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 2000, 20:9356-9363.
36. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
37. Eldar-Finkelman H., Seger R., Vandenheede J.R., Krebs E.G. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 1995, 270:987-990.
38. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993, 296:15-19.
39. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670.
40. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005, 19:159-170.
41. Cole A., Frame S., Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004, 377:249-255.
42. Lesort M., Jope R.S., Johnson G.V. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 1999, 72:576-584.
43. Hartigan J.A., Xiong W.C., Johnson G.V. Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun 2001, 284:485-489.
44. Kim L., Liu J., Kimmel A.R. The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 1999, 99:399-408.
45. Saito Y., Vandenheede J.R., Cohen P. The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J 1994, 303:27-31.
46. Sutherland C., Cohen P. The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett 1994, 338:37-42.
47. Stamos J.L., Chu M.L., Enos M.D., Shah N., Weis W.I. Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife 2014, 3:e01998.
48. Kaidanovich-Beilin O., Woodgett J.R. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 2011, 4:40.
49. Ng S.S., Mahmoudi T., Danenberg E., Bejaoui I., de Lau W., Korswagen H.C., et al. Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol Chem 2009, 284:35308-35313.
50. Suzuki T., Bridges D., Nakada D., Skiniotis G., Morrison S.J., Lin J.D., et al. Inhibition of AMPK catabolic action by GSK3. Mol Cell 2013, 50:407-419.
51. Sutherland C. What are the bona fide GSK3 substrates?. Int J Alzheimer[U+05F3]s Dis 2011, 2011:505607.
52. Linding R., Jensen L.J., Ostheimer G.J., van Vugt M.A., Jorgensen C., Miron I.M., et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007, 129:1415-1426.
53. Force T., Woodgett J.R. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009, 284:9643-9647.
54. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
55. Lee F.H., Kaidanovich-Beilin O., Roder J.C., Woodgett J.R., Wong A.H. Genetic inactivation of GSK3alpha rescues spine deficits in Disc1-L100P mutant mice. Schizophr Res 2011, 129:74-79.
56. MacAulay K., Doble B.W., Patel S., Hansotia T., Sinclair E.M., Drucker D.J., et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007, 6:329-337.
57. Goode N., Hughes K., Woodgett J.R., Parker P.J. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 1992, 267:16878-16882.
58. Gulen M.F., Bulek K., Xiao H., Yu M., Gao J., Sun L., et al. Inactivation of the enzyme GSK3alpha by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 2012, 37:800-812.
59. Brognard J., Sierecki E., Gao T., Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007, 25:917-931.
60. Beurel E., Mines M.A., Song L., Jope R.S. Glycogen synthase kinase-3 levels and phosphorylation undergo large fluctuations in mouse brain during development. Bipolar Disord 2012, 14:822-830.
61. Beurel E., Yeh W.I., Michalek S.M., Harrington L.E., Jope R.S. Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J Immunol 2011, 186:1391-1398.
62. Lau K.F., Miller C.C., Anderton B.H., Shaw P.C. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999, 54:85-91.
63. Chung Y.C., Chang K.J., Yang C.C., Lai M.T., Hsu C.P., Hsueh S.F., et al. Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer 2002, 95:1840-1847.
64. Hsueh S.F., Lai M.T., Yang C.C., Chung Y.C., Hsu C.P., Peng C.C., et al. Association of overexpressed proline-directed protein kinase F(A) with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer 2002, 95:775-783.
65. Yang S.D., Yu J.S., Yang C.C., Lee S.C., Lee T.T., Ni M.H., et al. Overexpression of protein kinase FA/GSK-3 alpha (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J Cell Biochem 1996, 61:238-245.
66. Yang S.D., Yu J.S., Lee T.T., Ni M.H., Yang C.C., Ho Y.S., et al. Association of protein kinase FA/GSK-3alpha (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression. J Cell Biochem 1995, 59:143-150.
67. Lee T.T., Ho Y.S., Yu J.S., Yang S.D. Overexpression of cellular activity and protein level of protein kinase FA/GSK-3 alpha correlates with human thyroid tumor cell dedifferentiation. J Cell Biochem 1995, 58:474-480.
68. Vincent E.E., Elder D.J., OFlaherty L., Pardo O.E., Dzien P., Phillips L., et al. Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation. PLoS One 2014, 9:e114725.
69. Cho Y.J., Yoon J., Ko Y.S., Kim S.Y., Cho S.J., Kim W.H., et al. Glycogen synthase kinase-3beta does not correlate with the expression and activity of beta-catenin in gastric cancer. APMIS 2010, 118:782-790.
70. Miyashita K., Kawakami K., Nakada M., Mai W., Shakoori A., Fujisawa H., et al. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res 2009, 15:887-897.
71. Salim T., Sjolander A., Sand-Dejmek J. Nuclear expression of glycogen synthase kinase-3beta and lack of membranous beta-catenin is correlated with poor survival in colon cancer. Int J Cancer 2013, 133:807-815.
72. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006, 12:5074-5081.
73. Naito S., Bilim V., Yuuki K., Ugolkov A., Motoyama T., Nagaoka A., et al. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res 2010, 16:5124-5132.
74. Bilim V., Ougolkov A., Yuuki K., Naito S., Kawazoe H., Muto A., et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009, 101:2005-2014.
75. Armanious H., Deschenes J., Gelebart P., Ghosh S., Mackey J., Lai R. Clinical and biological significance of GSK-3beta inactivation in breast cancer-an immunohistochemical study. Hum Pathol 2010, 41:1657-1663.
76. Campa V.M., Kypta R.M. Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct 2011, 6:4.
77. Li R., Erdamar S., Dai H., Sayeeduddin M., Frolov A., Wheeler T.M., et al. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res 2009, 29:2077-2081.
78. Darrington R.S., Campa V.M., Walker M.M., Bengoa-Vergniory N., Gorrono-Etxebarria I., Uysal-Onganer P., et al. Distinct expression and activity of GSK-3alpha and GSK-3beta in prostate cancer. Int J Cancer 2012, 131:E872-E883.
79. Chang C., Lee S.O., Yeh S., Chang T.M. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2014, 33:3225-3234.
80. Bastos D.A., Dzik C., Rathkopf D., Scher H.I. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology 2014, 28:693-699.
81. Yuan X., Cai C., Chen S., Chen S., Yu Z., Balk S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014, 33:2815-2825.
82. Truica C.I., Byers S., Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000, 60:4709-4713.
83. Yang F., Li X., Sharma M., Sasaki C.Y., Longo D.L., Lim B., et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002, 277:11336-11344.
84. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998, 95:15587-15591.
85. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454.
86. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002, 277:30935-30941.
87. Wang L., Lin H.K., Hu Y.C., Xie S., Yang L., Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004, 279:32444-32452.
88. Salas T.R., Kim J., Vakar-Lopez F., Sabichi A.L., Troncoso P., Jenster G., et al. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 2004, 279:19191-19200.
89. Gioeli D., Ficarro S.B., Kwiek J.J., Aaronson D., Hancock M., Catling A.D., et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002, 277:29304-29314.
90. Mazor M., Kawano Y., Zhu H., Waxman J., Kypta R.M. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004, 23:7882-7892.
91. Rinnab L., Schutz S.V., Diesch J., Schmid E., Kufer R., Hautmann R.E., et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?. Neoplasia 2008, 10:624-634.
92. Liao X., Thrasher J.B., Holzbeierlein J., Stanley S., Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004, 145:2941-2949.
93. Sun A., Shanmugam I., Song J., Terranova P.F., Thrasher J.B., Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 2007, 67:976-988.
94. Goc A., Al-Husein B., Katsanevas K., Steinbach A., Lou U., Sabbineni H., et al. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014, 5:775-787.
95. Schutz S.V., Schrader A.J., Zengerling F., Genze F., Cronauer M.V., Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011, 6:e25341.
96. Zhu Q., Yang J., Han S., Liu J., Holzbeierlein J., Thrasher J.B., et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011, 71:835-845.
97. Schutz S.V., Cronauer M.V., Rinnab L. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 2010, 109:1192-1200.
98. Liao X., Zhang L., Thrasher J.B., Du J., Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Therap 2003, 2:1215-1222.
99. Vene R., Larghero P., Arena G., Sporn M.B., Albini A., Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res 2008, 68:6987-6996.
100. Sun M., Song L., Li Y., Zhou T., Jope R.S. Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ 2008, 15:1887-1900.
101. Gao F., Al-Azayzih A., Somanath P.R. Discrete functions of GSK3alpha and GSK3beta isoforms in prostate tumor growth and micrometastasis. Oncotarget 2015, 6:5947-5962.
102. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004, 3:479-487.
103. Eldar-Finkelman H., Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 2011, 4:32.
104. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer[U+05F3]s disease. J Med Chem 2002, 45:1292-1299.
105. Dominguez J.M., Fuertes A., Orozco L., del Monte-Millan M., Delgado E., Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012, 287:893-904.
106. Lovestone S., Boada M., Dubois B., Hull M., Rinne J.O., Huppertz H.J., et al. A phase ii trial of tideglusib in Alzheimer[U+05F3]s disease. J Alzheimers Dis 2015, 45:75-88.
107. Tolosa E., Litvan I., Hoglinger G.U., Burn D., Lees A., Andres M.V., et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014, 29:470-478.
108. Hoglinger G.U., Huppertz H.J., Wagenpfeil S., Andres M.V., Belloch V., Leon T., et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014, 29:479-487.
109. del Ser T., Steinwachs K.C., Gertz H.J., Andres M.V., Gomez-Carrillo B., Medina M., et al. Treatment of Alzheimer[U+05F3]s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2013, 33:205-215.
110. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996, 93:8455-8459.
111. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668.
112. Ryves W.J., Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001, 280:720-725.
113. Yin Y., Kizer N.T., Thaker P.H., Chiappinelli K.B., Trinkaus K.M., Goodfellow P.J., et al. Glycogen synthase kinase 3beta inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci 2013, 14:16617-16637.
114. Grassilli E., Narloch R., Federzoni E., Ianzano L., Pisano F., Giovannoni R., et al. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res 2013, 19:3820-3831.
115. Plotkin B., Kaidanovich O., Talior I., Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003, 305:974-980.
116. Campa V.M., Baltziskueta E., Bengoa-Vergniory N., Gorrono-Etxebarria I., Wesolowski R., Waxman J., et al. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFkappaB and androgen receptor signaling in prostate cancer. Oncotarget 2014, 5:8173-8187.
117. Osolodkin D.I., Palyulin V.A., Zefirov N.S. Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors. Curr Pharm Des 2013, 19:665-679.